Apimeds Pharmaceuticals US, Inc (APUS)
$5.20+3.59%Close
BUYRECOVERY · day 5
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $8M
- Beta
- 0.15
- P/E (TTM)
- -0.14
- Short % float
- 14.12%
- Days to cover
- 1.0
- SI change
- +668.8%
- 1W
- +13.29%
- 1M
- +146.45%
- vs SPY 1W
- +12.87%
- vs SPY 1M
- +144.38%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 18
- VALUE
- 12
- GROWTH
- 41
- GARP
- 6
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-35.4%
REV YoY-
ROE-59.0%
EPS YoY-
ROA-45.6%
GROSS0
OP0
NET0
[VALUATION]
P/E TTM-0.14
P/E FWD-
SECTOR PE20.54
INDUSTRY PE14.03
P/B0.11
P/FCF-
EV/EBITDA-0.47
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E13.70
ALTMAN Z-
CURR RATIO0.51
ND/EBITDA-
BETA0.15
Company news
FAQ
- What is LOPJLB’s current signal on APUS?
- LOPJLB’s latest quantitative signal on Apimeds Pharmaceuticals US, Inc (APUS) is BUY in a RECOVERY regime. Signals are updated daily.
- What market regime is APUS in?
- Apimeds Pharmaceuticals US, Inc (APUS) is currently classified in the RECOVERY HMM market regime on LOPJLB.
- What does Apimeds Pharmaceuticals US, Inc (APUS) do?
- Apimeds Pharmaceuticals US, Inc. provides digital asset treasury solutions in bitcoin treasury infrastructure. The company was incorporated in 2020 and is based in Matawan, New Jersey. Apimeds Pharmaceuticals US, Inc. operates as a subsidiary of Inscobee., Inc.